CULLINAN ONCOLOGY LLC

NASDAQ: CGEM (Cullinan Therapeutics, Inc.)

Last update: 4 days ago, 6:52AM

8.16

-0.16 (-1.92%)

Previous Close 8.32
Open 8.25
Volume 332,389
Avg. Volume (3M) 434,722
Market Cap 481,559,936
Price / Book 0.870
52 Weeks Range
6.85 (-16%) — 21.01 (157%)
Earnings Date 6 Aug 2025 - 11 Aug 2025
Diluted EPS (TTM) -2.77
Total Debt/Equity (MRQ) 0.33%
Current Ratio (MRQ) 11.62
Operating Cash Flow (TTM) -150.21 M
Levered Free Cash Flow (TTM) -87.13 M
Return on Assets (TTM) -25.38%
Return on Equity (TTM) -36.57%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Cullinan Therapeutics, Inc. Bearish Bearish

AIStockmoo Score

1.5
Analyst Consensus 4.0
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 1.0
Technical Oscillators 0.5
Average 1.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CGEM 482 M - - 0.870
CGON 2 B - - 2.91
ORIC 786 M - - 3.65
PHAT 733 M - - -
SANA 589 M - - 2.82
ZVRA 490 M - - 12.04

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 4.55%
% Held by Institutions 116.27%

Ownership

Name Date Shares Held
Mpm Bioimpact Llc 31 Mar 2025 7,648,268
Lynx1 Capital Management Lp 31 Mar 2025 3,215,722
Blue Owl Capital Holdings Lp 31 Mar 2025 2,435,972
52 Weeks Range
6.85 (-16%) — 21.01 (157%)
Price Target Range
22.00 (169%) — 33.00 (304%)
High 33.00 (HC Wainwright & Co., 304.41%) Buy
Median 24.00 (194.12%)
Low 22.00 (Stifel, 169.61%) Buy
Average 26.33 (222.67%)
Total 3 Buy
Avg. Price @ Call 8.17
Firm Date Target Price Call Price @ Call
Stifel 11 Jun 2025 22.00 (169.61%) Buy 8.98
UBS 12 May 2025 24.00 (194.12%) Buy 7.91
HC Wainwright & Co. 16 Apr 2025 33.00 (304.41%) Buy 7.61

No data within this time range.

Date Type Details
04 Jun 2025 Announcement Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
01 Jun 2025 Announcement Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
29 May 2025 Announcement Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
22 May 2025 Announcement Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
08 May 2025 Announcement Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
29 Apr 2025 Announcement Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
23 Apr 2025 Announcement Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
16 Apr 2025 Announcement Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria